menu
    • menu

    Company profile for Anaveon

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Anaveon is committed to transforming immunological insights into life-saving therapies. With a vision to use our expertise in cutting-edge immunology to design and develop treatments that benefit patients and society, the team have the skills to make it happen and are ready to take Anaveon’s first drug into clinical trials.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AnaveonSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Technologiepark Basel Hochbergerstrasse 60C 4057 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://anaveon.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anaveon-ag/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anaveon appoints Dr. Richard Sachse as Chief Medical Officer
    Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

    19 Dec 2024

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2024-12-18/anaveon-appoints-dr-richard-sachse-as-chief-medical-officer

    PHARMAWEB
    19 Dec 2024
    Share Share
    Anaveon to Present Data on ANV700 & ANV600 at SITC 2024
    Anaveon to Present Data on ANV700 & ANV600 at SITC 2024

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971405/0/en/Anaveon-announces-presentation-of-new-data-on-development-compounds-ANV700-and-ANV600-at-the-Society-for-Immunotherapy-of-Cancer-2024-Annual-Meeting.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Anaveon appoints Dieter Weinand as Chair of its Board of Directors
    Anaveon appoints Dieter Weinand as Chair of its Board of Directors

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920713/0/en/Anaveon-appoints-Dieter-Weinand-as-Chair-of-its-Board-of-Directors.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share
    Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
    Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

    29 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/29/2889543/0/en/Anaveon-announces-IND-approval-of-ANV600-001-EXPAND-Phase-I-II-clinical-study.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share
    Anaveon announces presentation of a novel development compound at the 2023
    Anaveon announces presentation of a novel development compound at the 2023

    23 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/23/2632845/0/en/Anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-American-Association-for-Cancer-Research-Annual-Meeting.html

    GLOBENEWSWIRE
    23 Mar 2023
    Share Share
    Anaveon announces first patient dosed with ANV419 in a Ph I/II Study of ANV419
    Anaveon announces first patient dosed with ANV419 in a Ph I/II Study of ANV419

    16 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/16/2628317/0/en/Anaveon-announces-first-patient-dosed-with-ANV419-in-a-Phase-I-II-Study-of-ANV419-in-patients-with-multiple-myeloma.html

    GLOBENEWSWIRE
    16 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search